On November 10, 2025, the FDA announced it was removing the boxed warning, the so-called black box, from menopausal hormone therapy products. Headlines made it sound like a clean reversal. It is not that simple, and the details matter for anyone weighing treatment. Here is a precise read of what the label change did and did not do.

First, What a Boxed Warning Is

A boxed warning is the FDA's strongest safety label. It sits at the top of a drug's prescribing information, framed in black, flagging risks the agency considers serious. For more than twenty years, estrogen and estrogen-plus-progestin products carried one. That box listed cardiovascular disease, breast cancer, probable dementia and endometrial cancer. It shaped how a generation of doctors and patients talked about hormones, often by scaring both away from a treatment that, for many women, has a favorable balance.

What the November 2025 Change Removed

The FDA directed manufacturers to strip several risks from the boxed warning across hormone therapy products (HHS Fact Sheet, November 10, 2025; FDA press announcement). The removed language covers:

  • Cardiovascular disease. The blanket warning about heart attack and stroke risk is being taken out of the box.
  • Breast cancer. The breast cancer warning is being removed from the boxed section.
  • Probable dementia. This warning came from a subgroup of the WHI trials studying women aged 65 and older, and it is being removed.

The FDA also removed the boxed warning entirely from low-dose vaginal estrogen products, which act locally with very little absorption into the bloodstream. The Menopause Society had argued for years that applying the systemic warning to vaginal estrogen made no sense, and supported this part of the change.

Two other shifts in the label point the same way. The FDA added language supporting the start of hormone therapy for moderate to severe hot flashes in women under 60 or within ten years of menopause. It also dropped the old instruction to use "the lowest dose for the shortest duration," a phrase that pushed clinicians to undertreat.

What the Change Did Not Remove

This is the part the headlines skipped. The endometrial cancer warning stays in the boxed warning for systemic estrogen-alone products. The FDA did not seek to remove it.

The reason is settled biology, not caution. Estrogen tells the lining of the uterus to grow. Taken on its own by a woman who still has her uterus, it can overgrow that lining into hyperplasia and, over time, into endometrial cancer. The fix has been known for decades: pair systemic estrogen with a progestogen, usually micronized progesterone, which opposes that growth and protects the lining.

So the 2025 change does not mean estrogen alone is now safe for the uterus. If you have a uterus and take systemic estrogen, you still need progesterone alongside it. The only women who take estrogen alone are those who have had a hysterectomy and have no uterine lining to protect.

What It Does Not Mean

A few honest clarifications, because a label change is not new science:

  • It is not a finding that hormones are risk-free. Removing a warning reflects a reread of existing evidence and a judgment that the box overstated risk for the women most likely to use HRT. The Menopause Society reaffirmed that real risk remains for older women and those starting many years after menopause.
  • It does not change who should be cautious. A personal history of breast cancer, blood clots, stroke or active liver disease still weighs against systemic estrogen. Those are individual contraindications, label or no label.
  • It is being rolled out product by product. The FDA is working with each manufacturer to update labeling, so the exact wording you see on a given product may lag the announcement.

Why the FDA Moved Now

The boxed warning traced back to the Women's Health Initiative, the large trials published in 2002 and after. Those results were averaged across an older study population, with a mean age around 63, and the alarming numbers got generalized to women in their early 50s who they did not describe well. Later age-stratified analyses and the timing hypothesis showed a more favorable profile for women who start treatment near menopause. After an expert panel and a public comment period in 2025, the FDA concluded the old box no longer matched the evidence for the women most likely to be treated.

What This Means For You

If hot flashes, night sweats, or broken sleep are wearing you down, the label change removes a layer of fear that was doing more harm than good for many women under 60. It does not remove the need for an individual assessment. A clinician still needs your history, your cardiovascular and clot risk, whether you have a uterus, and your own preferences before recommending a route and dose. The endometrial rule is firm: uterus plus systemic estrogen means progesterone too.

The takeaway is narrow and useful. Less fear about heart, breast and brain for women starting near menopause. Same firm rule about protecting the uterus.

Reviewed By

[Reviewed by: clinician name, credential. Last reviewed: date.]

Want to know whether hormone therapy fits your history now that the warnings have changed? Start an intake and a licensed clinician will review your case.

This article is for education and is not a substitute for individual medical advice from your own clinician.